Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Phase of Trial: Phase II/III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sargramostim
- Indications Malignant melanoma
- Focus Therapeutic Use
- 27 Jun 2017 Status changed from recruiting to suspended due to Scheduled Interim Monitoring.
- 21 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2021.
- 30 Oct 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.